Gossamer Bio, Inc. (GOSS)
Gossamer Bio, Inc. (GOSS)
| Balance Sheets | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
|---|---|---|---|---|
| Cash and cash equivalents | 41,028 | 37,732 | 8,933 | 26,309 |
| Marketable securities | 58,187 | 99,200 | 171,291 | 186,609 |
| Receivable from contracts with collaborators | 9,252 | 12,227 | 9,243 | 7,579 |
| Prepaid expenses and other current assets | 16,069 | 18,485 | 14,522 | 15,401 |
| Total current assets | 124,536 | 167,644 | 203,989 | 235,898 |
| Property and equipment, net | 59 | 64 | 70 | 76 |
| Operating lease right-of-use assets | 3,906 | 4,133 | 4,354 | 4,568 |
| Other assets | 398 | 408 | 407 | 383 |
| Total assets | 128,899 | 172,249 | 208,820 | 240,925 |
| Accounts payable | 10,822 | 5,959 | 1,116 | 1,876 |
| Accrued research and development expenses | 17,395 | 21,662 | 17,736 | 15,601 |
| Current contract liabilities | 8,741 | 19,987 | 23,974 | 23,472 |
| Accrued expenses and other current liabilities | 19,548 | 15,827 | 19,291 | 12,645 |
| Total current liabilities | 56,506 | 63,435 | 62,117 | 53,594 |
| Long-term convertible senior notes | 198,763 | 198,508 | 198,257 | 198,009 |
| Operating lease liabilities - long-term | 3,213 | 3,460 | 3,700 | 3,934 |
| Long-term contract liabilities | 31,900 | 29,606 | 27,079 | 31,495 |
| Total liabilities | 290,382 | 295,009 | 291,153 | 287,032 |
| Common stock, 0.0001 par value 700,000,000 shares authorized as of march31, 2026 and december31, 2025 234,696,282 shares issued and outstanding as of march31, 2026, and 233,677,057 shares issued and outstanding as of december31, 2025 | 24 | 24 | 24 | 23 |
| Additional paid-in capital | 1,328,119 | 1,321,303 | 1,314,450 | 1,302,437 |
| Accumulated deficit | -1,485,602 | -1,438,938 | -1,391,700 | -1,343,479 |
| Accumulated other comprehensive loss | -4,024 | -5,149 | -5,107 | -5,088 |
| Total stockholders' deficit | -161,483 | -122,760 | -82,333 | -46,107 |
| Total liabilities and stockholders' equity (deficit) | 128,899 | 172,249 | 208,820 | 240,925 |